摘要
目的探讨泌尿系统感染患者尿微量白蛋白(MAU)及MAU/尿肌酐(UCr)比值升高的临床意义。方法 46例确诊为泌尿系统感染且伴MAU及MAU/UCr水平升高的门诊患者分别于抗感染治疗前及治疗后行尿常规及中段尿培养等检查,并监测MAU及MAU/UCr水平的变化。结果治疗前MAU升高者46例,平均水平为(94.8±151.8)mg/L;MAU/UCr升高者38例,平均水平为(15.9±16.6)g/molCr。治疗后平均MAU水平降低至(16.2±17.7)mg/L,MAU/UCr水平降低至(2.48±2.95)g/molCr,与治疗前相比差异有统计学意义的显著性(P<0.01)。结论在排除原发和继发性肾小球疾病,以及累及肾脏的系统性疾病后,如出现MAU及MAU/UCr水平升高提示其可能罹患肾盂肾炎。
Objective To evaluate the clinical significance of the increased levels of microalbuminuria （MAU） and MAU/urine creatinine （UCr） in patients with urinary tract infection. Methods Forty-six outpatients with confirmed urinary tract infection and increased MAU, MAU/UCr were performed urine routine and urine culture before and after treatment. The levels of MAU and MAU/UCr were also detected. Results Increased MAU was detected in 46 patients with an average level of （94.8 ±151.8） mg/L, and increased MAU/UCr was detected in 38 patients with an average level of （15.9±16.6） g/molCr before treatment. The average levels of MAU and MAU/UCr decreased to （16.2±17.7） mg/L and （2.48± 2.95）g/molCr respectively after treatment. The differences of the levels of MAU and MAU/UCr before and aider treatment were significant （P〈0.01）. Conclusion The increased levels of MAU and MAU/UCr maybe have a potential value on the diagnosis of pyelonephritis when primary and secondary glomerulopathy, as well as systemic disease which involve kidney are excluded.
出处
《世界临床药物》
CAS
2010年第7期422-425,共4页
World Clinical Drug
